Meeting
2023 ASCO Annual Meeting
Cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: Results of a phase II/III, placebo-controlled, randomised trial.
Authors
Antony Mersiades
NHMRC Clinical Trials Centre, The University of Sydney; Northern Beaches Hospital,, Sydney, NSW, Australia
Antony Mersiades , Adrienne Kirby , Martin R. Stockler , Annette Tognela , Ian N. Olver , Rachael L. Morton , Paul Haber , Anna Walsh , Yvonne Lee , Ehtesham A. Abdi , Stephen Della-Fiorentina , Morteza Aghmesheh , Peter Fox , Karen P. Briscoe , Jasotha Sanmugarajah , Gavin M. Marx , Ganessan Kichenadasse , Helen Wheeler , John Simes , Peter S. Grimison
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
ACTRN12616001036404
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 12019)
DOI
10.1200/JCO.2023.41.16_suppl.12019
Abstract #
12019
Poster Bd #
387
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Efficacy of haloperidol versus olanzapine for control of chemotherapy induced nausea and vomiting.
First Author: Soniya Dulal
Poster
2022 ASCO Annual Meeting
Efficacy of olanzapine, netupitant, and palonosetron in controlling nausea and vomiting associated with highly emetogenic chemotherapy in patients with breast cancer (OLNEPA).
First Author: Camilla Vieira de Reboucas
Poster
2018 ASCO Annual Meeting
Pilot and definitive randomised double-blind placebo-controlled trials evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting (CINV).
First Author: Antony Mersiades
Poster
2017 Gastrointestinal Cancers Symposium
Steroid-free regimen with aprepitant in preventing chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving FOLFOX chemotherapy: A randomized phase III trial.
First Author: Wenjing Wang